Pay to Marwadi

Company Profile

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal
BSE2229.00-101.05 (-4.34 % )
PREV CLOSE (Rs.) 2330.05
OPEN PRICE (Rs.) 2348.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 10380
TODAY'S LOW / HIGH (Rs.)2210.00 2348.00
52 WK LOW / HIGH (Rs.)1888.85 2766.85
NSE2231.55 -97.7 (-4.19 % )
PREV CLOSE(Rs.) 2329.25
OPEN PRICE (Rs.) 2344.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 2231.55 (545 )
VOLUME 190984
TODAY'S LOW / HIGH(Rs.) 2201.20 2346.90
52 WK LOW / HIGH (Rs.)1888.1 2767.1

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.54
TTM EPS (Rs.) 43.88
P/E Ratio 50.80
Book Value (Rs.) 227.40
Face Value (Rs.) 10
MCap (Rs. in Mn) 186072.13
Price/Earning (TTM) 41.93
Price/Sales (TTM) 9.70
Price/Book (MRQ) 9.80
PAT Margin (%) 16.53
ROCE (%) 22.71
Incorporation Year : 1995

Management Info :

Arvind Lal - Chairman Om Prakash Manchanda - Managing Director

Registered Office :

Address : Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone : 011-49885050

Registrar's Details : Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE
NEWS More
03May05-03-2024$Dr. Lal PathLabs informs about board meeting Dr. Lal PathLabs informs abo

Dr. Lal PathLabs has informed that a meeting of the Board of Directors is scheduled to be held on Friday, May 10, 2024 to consider and approve the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial year ended March 31, 2024 and to consider recommending Final Dividend, if any, on the Equity Shares of the Company for the Financial Year ended March 31, 2024. Further, in continuation to its letter dated March 26, 2024 and in line with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company is closed and shall re-open after 48 hours from the declaration of the aforesaid Financial Results.

The above information is a part of company’s filings submitted to BSE.

Dr. Lal PathLabs has informed that a meeting of the Board of Di..
26Mar03-26-2024$Dr. Lal PathLabs informs about closure of trading window Dr. Lal PathLabs informs abo

Dr. Lal PathLabs has informed that as per the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company's code for Prevention of Insider Trading, the Trading Window for dealing in Securities of the Company shall be closed from April 01, 2024 and would be re-opened after 48 hours from the date of announcement/ declaration of Audited Financial Results for the Quarter and Financial Year ending March 31, 2024.

The above information is a part of company’s filings submitted to BSE.


Dr. Lal PathLabs has informed that as per the provisions of the..
18Mar03-18-2024$ Board Meeting Outcome for Appointment Of Chief Executive Officer (Key Managerial Personnel) Board Meeting Outcome for A
Based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held today i.e., March 17, 2024, inter-alia, approved the re-designation of Mr. Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024
Based on recommendations of Nomination & Remuneration Committee..
18Mar03-18-2024$Dr. Lal PathLabs informs about outcome of committee meet Dr. Lal PathLabs informs abo

Dr. Lal PathLabs has informed that, based on recommendations of Nomination & Remuneration Committee, the Board of Directors in their meeting held on March 17, 2024, approved the re-designation of Shankha Banerjee by appointing him as Chief Executive Officer (CEO) and Key Managerial Personnel (KMP) with effect from May 21, 2024. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, is enclosed as ‘Annexure A’. Further, in view of above appointment and pursuant to Regulation 30(5) of Listing Regulations, the company has enclosed the details of the authorized persons for the purpose of determining materiality of any event or information, which shall be effective from May 21, 2024. Based on the decision of the above-named officials, the Compliance Officer shall be responsible for making disclosure to the Stock Exchange(s) and his contact details are also enclosed. The Board Meeting commenced at 11:00 am (IST) and concluded at 11:18 am (IST).

The above information is a part of company’s filings submitted to BSE.



Dr. Lal PathLabs has informed that, based on recommendations of..
01Feb02-01-2024$Dr. Lal PathLabs informs about earnings presentation Dr. Lal PathLabs informs abo

Dr. Lal PathLabs has informed that it attached a copy of Company's Q3 & 9M FY24 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2023, as approved by the Board of Directors in their meeting held on February 01, 2024.

The above information is a part of company’s filings submitted to BSE.

Dr. Lal PathLabs has informed that it attached a copy of Compan..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit8832924
Gross Profit 1195 3908
Operating Profit 14525073
Net Sales 476017690
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Vijaya Diagnostic (BSE)
 731.65 (7.75%)
M.Cap ( in Cr)
7500.59
RainbowChildrenS Med (BSE)
 1400.75 (3.45%)
M.Cap ( in Cr)
14217.85
Thyrocare Tech. (BSE)
 622.30 (0.95%)
M.Cap ( in Cr)
3295.25
Artemis Medicare (BSE)
 193.20 (2.96%)
M.Cap ( in Cr)
2645.21
Shalby (BSE)
 269.95 (1.10%)
M.Cap ( in Cr)
2915.72
Shareholding Pattern More
NON-INSTITUTION 9.56 %
MUTUAL FUNDS/UTI 6.79 %
PROMOTERS 54.6 %
FI/BANKS/INSURANCE 2.3 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes